Analyst Upgrades

• Expedia (EXPE) to buy from hold at Citigroup.
• Weatherford (WFT) to outperform from market perform at Wells Fargo.
• Abercrombie & Fitch (ANF) to buy from neutral at BofA/Merrill.
• MDC Holdings (MDC) to outperform from neutral at Credit Suisse.
• AutoNavi (AMAP) to buy from neutral at Goldman.
• Ciena (CIEN) and Nvidia (NVDA) to neutral from underweight at JPMorgan.
• Canadian Pacific (CP) to outperform from market perform at Raymond James.
• First Midwest (FMBI) and Quiksilver (ZQK) to buy from hold at Jefferies.
• Sonic (SONC) to neutral from negative at Susquehanna.
• MIPS Technologies (MIPS) to buy from hold at Benchmark Co.
• Arrow Electronics (ARW) and Avnet (AVT) to buy from hold at Stifel Nicolaus.

Continue reading Analyst Calls: ANF, BBBY, CIEN, CP, EXPE, ICE, NVDA, QCOM, SONC ...

Analyst Calls: ANF, BBBY, CIEN, CP, EXPE, ICE, NVDA, QCOM, SONC ... originally appeared on BloggingStocks on Tue, 08 Mar 2011 11:40:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Chesapeake (CHK) to buy from hold at Canaccord.
• Biogen (BIIB) and Regeneron (REGN) to outperform from sector perform at RBC Capital.
• Caribou Coffee (CBOU) to outperform from neutral and Encore Energy (ENP) to neutral from underperform at RW Baird.
• Fluor (FLR) to market perform from underperform at BMO Capital.
• Hornbeck Offshore (HOS) to conviction buy from neutral at Goldman.
• Saks (SKS) and Zale (ZLC) to neutral from underperform at BofA/Merrill.

Continue reading Analyst Calls: BIIIB, CBOU, CELG, CHK, CIEN, HOS, LULU, RHT, SKS, ZLC ...

Analyst Calls: BIIIB, CBOU, CELG, CHK, CIEN, HOS, LULU, RHT, SKS, ZLC ... originally appeared on BloggingStocks on Thu, 24 Feb 2011 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Oppenheimer upgraded Teva (TEVA) to outperform from perform. The firm expects the company to generate strong 2H10 earnings and thinks the competition created by Novartis's (NVS) Gilenia will be limited.
• Citigroup upgraded Celanese (CE) to buy from hold, citing valuation and the company's move to add assets in China, as well as possible takeover interest.
• Needham raised Stereotaxis (STXS) to buy from hold as the firm thinks that strong clinical data recently announced by the company could result in faster adoption rates of its robotic surgery.
• BMO Capital upgraded Smurfit-Stone Container (SSCC) given strength in the containerboard market.
• Melco Crown (MPEL) was upgraded to buy from neutral at UBS.
• Goldman Sachs raised Temple-Inland (TIN) to buy from neutral.
• Barclays upgraded Lloyds Banking (LYG) to equal weight from underweight.

Continue reading Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ...

Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ... originally appeared on BloggingStocks on Thu, 09 Sep 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Smurfit-Stone (SSCC) to buy from hold after raising its estimates for containerboard names and upped its target for shares to $28 from $22. The firm also raised its price target for International Paper (IP) to $38 from $32, for Packaging Corp. (PKG) to $33 from $28, for Temple-Inland (TIN) to $31 from $28, for Greif (GEF) to $67 from $65, and for Rock-Tenn (RKT) to $70 from $65. All stocks are buy rated.
• ThinkEquity upgraded VMware (VMW) to buy from hold and has a $90 price target on the stock. The firm expects VMware to benefit from increased virtual infrastructure adoption and improving vSphere solutions.
• Needham upgraded Cavium Networks (CAVM) to strong buy from buy, citing the recent pullback in shares following Cisco's (CSCO) cautious commentary. The firm has a $37 target on the stock.
• Intercontinental Exchange (ICE) was upgraded to outperform from neutral at Credit Suisse.
• MedAssets (MDAS) was upgraded to buy from hold at Auriga.
• Brookfield Properties (BPO) was upgraded to buy from hold at Citigroup.

Continue reading Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ...

Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ... originally appeared on BloggingStocks on Mon, 16 Aug 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Wells Fargo upgraded T. Rowe Price (TROW) to outperform from market perform, citing strong flows and a potential recovery in the U.S. equity markets.
• UBS upgraded BorgWarner (BWA) to buy from neutral and raised its price target to $50 from $48. The firm expects BorgWarner to benefit from fuel economy regulation.
• Cowen upgraded Celgene (CELG) to neutral from underperform, citing improved fundamentals and valuation for the upgrade.
• TRW Automotive (TRW) was upgraded to overweight from equal weight at Morgan Stanley.
• Finish Line (FINL) was upgraded to buy from hold at Citigroup.
• Jazz Pharmaceutical (JAZZ) was upgraded to overweight from equal weight at Barclays.

Continue reading Analyst Calls: AMZN, BWA, CELG, FINL, MMC, NLY, PPO, ROSE, SNDA, TROW, VVUS ...

Analyst Calls: AMZN, BWA, CELG, FINL, MMC, NLY, PPO, ROSE, SNDA, TROW, VVUS ... originally appeared on BloggingStocks on Tue, 15 Jun 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Auriga upgraded Cisco (CSCO) to buy from hold, citing the company's improving strategic position in data centers.
• Blue Nile (NILE) was raised to buy from hold by Citigroup due to the recent pullback in shares.
• DuPont Fabros (DFT) was upgraded to buy from neutral at UBS, which said that said fundamentals in the data center space have been improving.
• Baird upgraded Sterling Bancshares (SBIB) to neutral from underperform based on valuation.
• Goldman Sachs upgraded Bristol-Myers (BMY) to buy from neutral.
• Amazon.com (AMZN) was raised to conviction buy from buy by Goldman.
• Jefferies upgraded Celgene (CELG) to buy from hold.

Continue reading Analyst Calls: AAPL, ABT, AMZN, BMY, CSCO, DNB, EAT, INTU, NILE ...

Analyst Calls: AAPL, ABT, AMZN, BMY, CSCO, DNB, EAT, INTU, NILE ... originally appeared on BloggingStocks on Mon, 07 Jun 2010 11:20:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Oppenheimer upgraded Williams-Sonoma (WSM) to outperform from perform. Opco believes the company's business model is being underappreciated by investors and upped its target price for shares to $40 from $26.
• BMO Capital upgraded Tractor Supply (TSCO) to market perform from underperform and set a $75 target. The firm upgraded the stock after the company's positive preannouncement.
• JCPenney (JCP) was upgraded to conviction buy from neutral at Goldman.
• DISH Network (DISH) was upgraded to buy from neutral at UBS.
• BJ's Wholesale (BJ) was upgraded to neutral from underperform at Credit Suisse.
• Taseko Mines (TGB) was upgraded to buy from hold at TD Newcrest.

Continue reading Analyst Calls: AA, BJ, CELG, DISH, JCP, MGM, TJX, TSCO, WSM ...

Analyst Calls: AA, BJ, CELG, DISH, JCP, MGM, TJX, TSCO, WSM ... originally appeared on BloggingStocks on Fri, 09 Apr 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
• JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
• Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
• Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
• Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
• Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.

Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ... originally appeared on BloggingStocks on Fri, 12 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

Continue reading Celgene Remains in an Uptrend

Celgene Remains in an Uptrend originally appeared on BloggingStocks on Mon, 21 Dec 2009 17:00:00 EST. Please see our terms for use of feeds.

Continue reading Celgene Blood Cancer Drug Found Effective

Celgene Blood Cancer Drug Found Effective originally appeared on BloggingStocks on Fri, 18 Dec 2009 13:00:00 EST. Please see our terms for use of feeds.

From TheStreet.com Network

• Ariad Upgraded, Xenoport Drug Delayed: BioBuzz
• Holiday Deals Heat Up at Big Retailers

Continue reading Cramer on BloggingStocks: Pelosi can't kill the health care sector

Cramer on BloggingStocks: Pelosi can't kill the health care sector originally appeared on BloggingStocks on Mon, 09 Nov 2009 10:10:00 EST. Please see our terms for use of feeds.

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading biotechnology company.

Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA.

"Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging others involved in stem cell research.

Continue reading Celgene (CELG): Bet on biotech for 'offense and defense'

Celgene (CELG): Bet on biotech for 'offense and defense' originally appeared on BloggingStocks on Tue, 27 Oct 2009 11:20:00 EST. Please see our terms for use of feeds.

Continue reading Celgene is poised to break-out to the upside

Celgene is poised to break-out to the upside originally appeared on BloggingStocks on Fri, 09 Oct 2009 15:00:00 EST. Please see our terms for use of feeds.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

Continue reading Celgene (CELG): Cancer progress boosts biotech

Celgene (CELG): Cancer progress boosts biotech originally appeared on BloggingStocks on Wed, 19 Aug 2009 14:00:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Jefferies upgraded Autodesk (NASDAQ: ADSK) to Buy from Hold after the firm's channel checks indicated the company's business is stabilizing. Jefferies raised its target on shares to $27 from $20.
• Citigroup upgraded Veeco (NASDAQ: VECO) to Buy from Hold on expectations LED order momentum will continue and cost discipline will help margin leverage. Citi raised its target on shares to $24 from $8.
• Deutsche Bank upgraded Domtar (NYSE: UFS) to Buy from Hold on expectations earnings will improve meaningfully over the next year. The firm keeps a $24 price target on the stock.
• Varian (NASDAQ: VARI) was upgraded to Equal Weight from Underweight at Barclays.
• Air Products (NYSE: APD) was upgraded to Overweight from Neutral at JPMorgan.
• U.S. Steel (NYSE: X) was upgraded to Buy from Neutral at Goldman.

Continue reading Analyst upgrades, downgrades and initiations: AMGN, CS, DB, LEN, MET, SNI, X ...

Analyst upgrades, downgrades and initiations: AMGN, CS, DB, LEN, MET, SNI, X ... originally appeared on BloggingStocks on Tue, 28 Jul 2009 11:20:00 EST. Please see our terms for use of feeds.

From TheStreet.com Network

• Coming Week: More Earnings, Upside
• Higher Medical Costs Crimp Aetna Profits

Continue reading Cramer on BloggingStocks: The health care bargain

Cramer on BloggingStocks: The health care bargain originally appeared on BloggingStocks on Mon, 27 Jul 2009 10:00:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Citigroup upgraded Kraft Foods (NYSE: KFT) to Buy from Hold as it believes the company's domestic retail business is improving while input cost inflation pressures are beginning to moderate. Citi raised its target on shares to $32 from $28.
• Jefferies upgraded Sybase (NYSE: SY) to Buy from Hold as it believes slowing core IPG licenses in the second half of 2009 are now reflected in guidance. The firm raised its target on shares to $41 from $34.
• Canaccord said Apple's (NASDAQ: AAPL) decision to ad video functionality into the iPod lineup is "very positive" as it expands its market into the low-end camcorder area. The firm, which upgraded shares to Buy from Hold and raised its target to $200 from $150, also views the launch of iPhone 3GS in all countries by the end of Q4 as another catalyst.
• Rio Tinto (NYSE: RTP) was upgraded to Buy from Hold at Societe Generale.
• Renasant Corp. (NASDAQ: RNST) was upgraded to Overweight from Equal Weight at Stephens.
• America Movil (NYSE: AMX) was upgraded to Neutral from Sell at Pali Capital.

Continue reading Analyst upgrades, downgrades and initiations: AAPL, AMX, COST, KFT, LMT, RTP ...

Analyst upgrades, downgrades and initiations: AAPL, AMX, COST, KFT, LMT, RTP ... originally appeared on BloggingStocks on Wed, 22 Jul 2009 11:30:00 EST. Please see our terms for use of feeds.

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

Continue reading Time to scoop up some shares of Celgene

Time to scoop up some shares of Celgene originally appeared on BloggingStocks on Fri, 19 Jun 2009 17:00:00 EST. Please see our terms for use of feeds.

• Citigroup upgraded Cooper Industries (NYSE: CBE) to Hold from Sell to reflect improving macro indicators and a belief negative earnings revisions are unlikely going forward. The firm raised its target price to $37 from $28.
  
• Royal Bank of Scotland upgraded Siemens (NYSE: SI) to Buy from Hold on expectations the company will benefit from an economic recovery.
  
• Banc of America/Merril upgraded State Street (NYSE: STT) to Buy from Neutral and raised their price target to $50 from $40 following stress test results that show the company does not need additional capital. The analyst said the news "clears one of the bars on capital concerns."
  
• Teradata (NYSE: TDC) was raised to Market Weight from Underweight at Thomas Weisel.
  
• Target (NYSE: TGT) was lifted to Overweight from Neutral at JP Morgan.
  
• Diageo (NYSE: DEO) was upgraded at UBS to Neutral from Sell.

Continue reading Analyst upgrades, downgrades and initiations: STT, TGT, PEP, V, WMT ...

Analyst upgrades, downgrades and initiations: STT, TGT, PEP, V, WMT ... originally appeared on BloggingStocks on Fri, 08 May 2009 11:00:00 EST. Please see our terms for use of feeds.